

1 **Gene expression signatures identify pediatric patients with multiple**
2 **organ dysfunction who require advanced life support in the intensive**
3 **care unit**

4 **Running title:** Transcriptional signature for multiple organ dysfunction
5 syndrome trajectory

6
7 Rama Shankar (ramashan@msu.edu)^{1,2}, Mara L. Leimanis
8 (Mara.Leimanis@spectrumhealth.org)^{1,3}, Patrick A. Newbury (rnewbury@gmail.com)^{1,2}, Ke Liu
9 (liuke2@msu.edu)^{1,2}, Jing Xing (xingjin1@msu.edu)^{1,2}, Derek Nedveck
10 (dnedveck@gmail.com)⁴, Eric J. Kort (eric.kort@helendevoschildrens.org)^{1,5,6}, Jeremy W
11 Prokop (prokopje@msu.edu)^{1,2}, Guoli Zhou (zhoug@msu.edu)⁷, André S Bachmann
12 (bachma26@msu.edu)¹, Bin Chen (chenbi12@msu.edu)^{1,2*}, Surender Rajasekaran
13 (surender.rajasekaran@spectrumhealth.org)^{1,3,4*}

14
15
16 **1** Department of Pediatrics and Human Development, College of Human Medicine, Michigan State
17 University, Grand Rapids, MI 49503, USA
18 **2** Department of Pharmacology and Toxicology, College of Human Medicine, Michigan State University,
19 Grand Rapids, MI 49503, USA
20 **3** Pediatric Intensive Care Unit, Helen DeVos Children's Hospital, 100 Michigan Street NE, Grand Rapids,
21 MI, 49503, USA
22 **4** Office of Research, Spectrum Health, 15 Michigan Street NE, Grand Rapids, MI 49503, USA
23 **5** DeVos Cardiovascular Program, Van Andel Research Institute and Fredrik Meijer Heart and Vascular
24 Institute/Spectrum Health, Grand Rapids, MI 49503, USA
25 **6** Pediatric Hospitalist Medicine, Helen DeVos Children's Hospital, 100 Michigan Street NE, Grand Rapids,
26 MI, 49503, USA
27 **7** Biomedical Research Informatics Core (BRIC), Clinical and Translational Sciences Institute (CTSI),
28 Michigan State University, East Lansing, MI 48824, USA

29
30 * Correspondence: Dr. Bin Chen (chenbi12@msu.edu) and Dr. Surender Rajasekaran
31 (surender.rajasekaran@spectrumhealth.org)

32

33 **Abstract**

34 **Background:** Multiple organ dysfunction syndrome (MODS) occurs in the setting of a
35 variety of pathologies including infection and trauma. Some of these patients will further
36 decompensate and require extra corporeal membrane oxygenation (ECMO) as a
37 palliating maneuver to allow time for recovery of cardiopulmonary function. The
38 molecular mechanisms driving progression from MODS to cardiopulmonary collapse
39 remain incompletely understood, and no biomarkers have been defined to identify those
40 MODS patients at highest risk for progression to requiring ECMO support. We
41 hypothesize that molecular features derived from whole blood transcriptomic profiling
42 either alone or in combination with traditional clinical and laboratory markers can
43 prospectively identify these high risk MODS patients in the pediatric intensive care unit
44 (PICU).

45

46 **Design/Methods:** Whole blood RNA-seq profiling was performed for 23 MODS patients
47 at three time points during their ICU stay (at diagnosis of MODS, 72 hours after, and 8
48 days later), as well as four healthy controls undergoing routine sedation. Of the 23
49 MODS patients, six required ECMO support (ECMO patients). The predictive power of
50 conventional demographic and clinical features was quantified for differentiating the
51 MODS and ECMO patients. We then compared the performance of markers derived
52 from transcriptomic profiling including (1) transcriptomically imputed leukocyte subtype
53 distribution, (2) relevant published gene signatures and (3) a novel differential gene
54 expression signature computed from our data set. The predictive power of our novel
55 gene expression signature was then validated using independently published datasets.

56 **Results:** None of the five demographic characteristics and 14 clinical features, including
57 The Pediatric Logistic Organ Dysfunction (PELOD) score, could predict deterioration of
58 MODS to ECMO at baseline. From previously published sepsis signatures, only the
59 signatures positively associated with patients mortality could differentiate ECMO
60 patients from MODS patients, when applied to our transcriptomic dataset (P -value
61 ranges from 0.01 to 0.04). Deconvolution of bulk RNA-Seq samples suggested that
62 lower neutrophil counts were associated with increased risk of progression from MODS
63 to ECMO (P -value = 0.03, OR=2.82 [95% CI 0.63– 12.45]). A total of 28 genes were
64 differentially expressed between ECMO and MODS patients at baseline (\log_2 fold
65 change ≥ 1 or ≤ -1 with false discovery rate ≤ 0.2). These genes are involved in protein
66 maintenance and epigenetic-related processes. Further univariate analysis of these 28
67 genes suggested a signature of six DE genes associated with ECMO (OR > 3.0, P -
68 value ≤ 0.05). Notably, this contains a set of histone marker genes, including *H1F0*,
69 *HIST2H3C*, *HIST1H2AI*, *HIST1H4*, and *HIST1H1B*, that were highly expressed in
70 ECMO. A risk score derived from expression of these genes differentiated ECMO and
71 MODS patients in our dataset (AUC = 0.91, 95% CI 0.79-0.1.00, P -value = 7e-04) as
72 well as validation dataset (AUC= 0.73,95% CI 0.53-0.93, P -value = 2e-02).

73
74 **Conclusions:** This study identified lower neutrophils and upregulation of specific
75 histone related genes as a putative signature for deterioration of MODS to ECMO. This
76 study demonstrates that transcriptomic features may be superior to traditional clinical
77 methods of ascertaining severity in patients with MODS.

78

79 **Author summary**

80 **Why was this study done?**

- 81 ● Multiple organ dysfunction syndrome (MODS) is a major cause of mortality and
82 morbidity in critically ill pediatric patients who survive the initial physical insult.
- 83 ● A variety of triggers including trauma and infections can lead to MODS in
84 pediatric patients.
- 85 ● The clinical condition of some MODS patients improve while others deteriorate,
86 needing resource-intensive life support such as extracorporeal membrane
87 oxygenation (ECMO).
- 88 ● Mortality is uncommon in PICUs and the need for advanced life support devices,
89 such as ECMO can serve as proxy for mortality.
- 90 ● The decision to initiate ECMO in pediatric patients is often subjective made by a
91 committee of physicians that include surgeons, intensivists and a variety of other
92 subspecialists often in the absence of objective data.
- 93 ● Despite decades of research, no diagnostic criteria or biomarker has been
94 identified that comprehensively assesses severity in MODS patients who may
95 need subsequent ECMO support in the hyperacute phase of injury.
- 96 ● We systematically assessed clinical and transcriptional features as biomarkers
97 for the prediction of the ECMO patients.

98

99 **What did the researcher do and find?**

- 100 ● We investigated various clinical and transcriptional features in 27 patients with
101 MODS at multiple time points (4 CT, 17 MODS, 6 ECMO) at baseline (0h).

- 102 ● We observed that immune response pathways (monocytes, cytokines, NF-kB,
103 and inflammation) were activated in the initiation of MODS, whereas neutrophil
104 level was decreased during deterioration of MODS to ECMO.
- 105 ● A total of 51 DE genes were identified in MODS compared to CT and 28 DE in
106 ECMO compared to MODS at baseline (0h).
- 107 ● We identified the enrichment of immune-related and glycogenolysis processes in
108 MODS compared to CT and enrichment of protein maintenance, DNA repair and
109 epigenetic-related processes in ECMO compared to MODS at baseline (0h).
- 110 ● Logistic regression was used to identify a signature of 6 genes strongly
111 associated with ECMO decision and this signature could help to diagnose MODS
112 patients requiring ECMO.
- 113 ● The transcriptomic signature-based risk scores were further evaluated in an
114 independent cohort.

115

116 **What do these findings mean?**

- 117 ● The compromised level of neutrophils and activation of gene markers including a
118 few histone genes could be used as putative signature for diagnosing the
119 deterioration of MODS to ECMO.
- 120 ● A risk score derived from signature genes could be used to predict the need for
121 ECMO.
- 122 ● This score is superior to traditional clinical criteria and severity scores used in the
123 Pediatric ICU.

- 124 • The transcriptional signature derived in this study could potentially be used to
125 identify patients in the hyperacute phase of injury that may need higher levels of
126 support like ECMO enabling the selection of an appropriate treatment plan.

127

128 **Abbreviation:** Multiple organ dysfunction syndrome, MODS; Extracorporeal Membrane
129 Oxygenation, ECMO; patients did not develop MODS, no-MODS; pediatric intensive
130 care unit, PICU; Differentially expressed, DE; False discovery rate, FDR; Area under
131 curve, AUC; principal component analysis, PCA; Odds ratio, OR.

132

133 **Introduction**

134 Multiple organ dysfunction syndrome (MODS) is common in the pediatric intensive care
135 unit (PICU), being diagnosed in the majority of patients with sepsis as well as many
136 trauma patients [1]. MODS complicates a wide range of pathologies including severe
137 hypoxemia, cardiorespiratory arrest, shock, trauma, acute pancreatitis, gut
138 malperfusion, acute leukemia, solid organ or hematopoietic stem cell transplantation,
139 hemophagocytic lymphohistiocytosis, and thrombotic microangiopathy [2].
140 Contemporary management of MODS is entirely supportive, and focused on addressing
141 the underlying disease process.

142 Some pediatric patients who develop MODS deteriorate and require intensive life
143 support in the form of Extracorporeal Membrane Oxygenation (ECMO). It has been
144 observed that pediatric patients requiring ECMO have a 50-60% mortality rate [3]. The
145 decision to initiate ECMO remains subjective based on the empirical experience of the
146 multidisciplinary care team. Establishment of objective markers of what patients will

147 require ECMO support would simplify the decision making process and potentially
148 enable earlier intervention for these patients. However, no clinical scoring tool or
149 molecular biomarker has been developed to identify the patients who may require
150 subsequent advanced support; therefore, developing biomarkers for identifying MODS
151 patients at high risk of requiring ECMO support is a critical unmet need.

152 Whole blood transcriptomic profiling has been evaluated to perform risk-
153 stratification of sepsis patients, predict mortality in sepsis and better understand the
154 pathogenesis of MODS [4]. A number of published gene expression signatures shed
155 light on the molecular mechanism of MODS [5,6]. However, none of the signatures were
156 developed with a view towards identifying patients that require ECMO support.

157 In this work, we present a cohort of MODS patients, a subset of whom
158 progressed to requiring ECMO support (MODS vs ECMO) and healthy controls (CT).
159 Here we use the term MODS to denote those MODS patients that did not require ECMO
160 and ECMO for MODS patients deteriorated to needing ECMO support. These patients
161 were assessed using a combination of conventional demographic and clinical markers,
162 as well as whole blood transcriptomic profiling in an effort to identify diagnostic markers
163 that can distinguish between the MODS and ECMO patient population.

164

165 **Methods**

166 **Patients and blood sampling**

167 The IRB of this study (2016-062-SH/HDVCH) was approved by Spectrum Health on
168 May 17, 2016. All the patients were minors and their parents were consented prior to
169 recruitment into our study. Every parent gave consent. After IRB approval, a short-term

170 longitudinal design was adopted to assess the transcriptomic profiles of patients from
171 the PICU at Helen DeVos Children's Hospital, Michigan. Critically ill patients, meeting
172 criteria for MODS as determined by clinical observations, were screened for eligibility
173 and consented. Blood samples were collected at three time points: at recognition of
174 MODS (0h), 72 hours after, and 8 days later (N=27). Samples were collected in
175 PaxGene® tubes and stored at -80°C. Healthy controls (N=4) were patients that
176 presented for same day sedation. Samples from each control patient were obtained only
177 once and were reported as 0h. Of the 23 MODS patients, 6 required ECMO support.
178 From admission to day 8, 47% of the MODS patients were discharged to home or out of
179 the ICU to a medical floor. Patients who left the ICU did not have further blood draws.
180 One patient from the ECMO group died during the study and two other MODS patients
181 died six months later.

182

183 **Sequencing**

184 RNA samples were prepared using KAPA RNA HyperPrep Kit, and sequenced on
185 an Illumina NextSeq500. Using ribosomal reduction RNAseq methodology, we were able
186 to capture both cellular and acellular RNA signatures of all PICU patients.

187

188 **Validation Data Sets**

189 For validation, we were unable to identify any analogous publicly available gene
190 expression datasets that included pediatric MODS patients at multiple time points. We
191 therefore chose a dataset describing an adult cohort (23-63 years) developed MODS in
192 the hyperacute phase of trauma [7]. This dataset was used as an independent cohort to

193 validate our signature genes. The MODS patients in this validation dataset were
194 categorized into MODS and noMODS (patients did not develop MODS) as described in
195 patient demographics [7]. In addition, a single cell RNA-Seq dataset was also available
196 for adult ECMO patients [8]. We used the immune cell markers from this dataset to
197 validate our immune response analysis.

198

199 **Bioinformatics analysis**

200 **RNA-Seq data analysis.** All the sequencing reads were mapped on Hg38
201 transcriptome using the ENSEMBL GRCh38.p3 annotation with the STAR aligner [9].
202 The edgeR package [10] was used for quantification of differentially expressed (DE)
203 genes with criteria: \log_2 fold change ≥ 1 or ≤ -1 with adjusted *P*-value (False Discover
204 Rate) < 0.20 . DE genes were identified between the two groups in all the three-time
205 points separately. The DE genes were used for co-expression network analysis using
206 CEMiTools package [11]. The gene ontology (GO) enrichment of DE genes was
207 performed using the clusterProfiler R package [12]. Biological processes with adjusted
208 *P*-value ≤ 0.01 were considered as significantly enriched. Dotplot function provided in
209 clusterProfiler was used to visualize enriched pathways. In addition, gene interaction
210 network was visualized using STRING: functional protein association network
211 (<https://string-db.org/>).

212

213 **Immune Cell Deconvolution.** CIBERSORT was used to estimate the relative
214 composition of immune cells in bulk RNA-Seq samples [13] using a machine learning
215 model named as nu-support vector regression (*v*-SVR) [14]. For each patient, a

216 complete blood count (CBC) was obtained upon presentation as part of their standard of
217 care clinical evaluation. We were therefore able to calculate estimated absolute counts
218 for each leukocyte subpopulation. This was done by multiplying the proportion for each
219 subpopulation as determined by CIBERSORT to the total white blood cell count from
220 the CBC. This analysis was validated by comparing the absolute neutrophil counts
221 (ANC) as estimated by CIBERSORT with the ANC reported by the clinical laboratory.

222

223 **Statistical Analysis**

224 All plots and statistical analyses were carried out using R programming language
225 (v3.5.1) (<https://www.r-project.org/>). By default, two-sided student's t-test was performed
226 to compute the significance between two groups. The generalized linear model function
227 (glm) was used to calculate odds ratio (OR). Principal component analysis (PCA) of
228 gene expression profiles was performed using the prcomp function. The risk score was
229 estimated using the signature gene expression for each patient based on the geometric
230 mean. The geometric mean for x_1, x_2, \dots, x_n was calculated as follows:

$$231 \quad \left(\prod_{i=1}^n x_i\right)^{\frac{1}{n}} = \sqrt[n]{x_1 x_2 \dots x_n}$$


232 A risk score was further used to re-classify patients into two groups and receiver
233 operating characteristic (ROC) and area under curve (AUC) were adopted to assess the
234 performance using the pROC package [15].

235

236 **Results**

237 The workflow of the study is summarized in Fig. 1. Patient demographics and baseline
238 clinical parameters are provided in Table 1, with 72h and 8 day values presented in

239 supplemental Table S1. In total, five demographic characteristics (i.e., age, gender,
240 BMI, weight, height) and 14 different clinical features were examined for all patients.
241 There was high variation between MODS and ECMO for many clinical parameters (e.g.
242 platelet count), diluting the predictive power of these measures. Some outcomes
243 differed significantly between MODS and ECMO, specifically the renal failure rate (89%
244 in MODS and 100% in ECMO) and liver failure rate (30% in MODS and 50% in ECMO.
245 However, no baseline demographic or clinical parameter, including PELOD score was
246 predictive of progression from MODS to ECMO. This observation highlighted the need
247 to explore molecular features for identifying risk markers.



248

249

250

251 **Fig. 1 An overview of the analysis.** DGE: Differential gene expression.

252

253

254 **Table 1: Patients demographics at baseline (Pre-ECMO,0h) time point.**

255

RNA-Seq cohort				
Demographics	Control	MODS	ECMO	P-value
Time	0h	0h	0h	-
Number	4	17	6	-
Age (months)	84.75(28-122)	90(0.14-202)	63.25(0.5-202)	0.54
Male	2	10	5	0.36
Female	2	7	1	0.36
BMI	17(14-21)	20.3(13-38.5)	19(14-32.4)	0.74
Weight	26.5(12-35)	42.85(3.5-178)	25.87(3.9-81)	0.35
Height	122(80-142)	103(51-157)	90(53-160)	0.59
Mortality	-	2	1	
Clinical Features				
Liver Failure (%)	-	30	50	-
Bilirubin	-	0.92(0.1-5.6)	0.51(0.1-1.1)	0.28
AST	-	258.88(13-3296)	215.67(7-726)	0.85
Albumin	-	2.35(1.6-3.5)	2.35(1.9-2.8)	0.96
CRP	-	83.75(0.3-234)	75.75(2.8-211)	0.87
Renal Failure (%)	-	89	100	-
Creatinine	-	0.65(0.13-0.29)	0.77(0.22-0.29)	0.71
Lactate	-	2.2(0.9-4.6)	6.05(0.6-14.5)	0.19
WBC	-	14.9(3.95-62.6)	12.67(4.6-20)	0.56
platelet	-	232(37-718)	208(92-378)	0.68
PELOD Score	-	14.37(1-32)	12.5(10-20)	0.21
Bacterial infection (%)	-	35	33	
Viral infection (%)	-	52	50	
Inotrope usage		88	100	
Respiratory failure (%)	-	100	100	
Neurological (%)	-	23	33	

Where relevant, mean(range). T-test and fisher's exact test was used to compute P-value between MODS and ECMO.

256

257


258 **Immune cells deconvolution and transcriptome analysis**

259 Immune responses were examined for individual patients and compared to elucidate
260 their role. The relative proportions of immune cell subtypes were estimated using
261 CIBERSORT based on bulk RNA-Seq data. WBC counts obtained upon arrival in the
262 emergency department were used to quantify the absolute abundance of immune cell
263 subtypes. The ANC as determined by the clinical laboratory and the ANC derived from
264 CIBERSORT were high correlated (correlation value 0.97) (Figure S1), suggesting the
265 high fidelity of the inferred leukocyte subtype composition. Comparison of neutrophils
266 between ECMO and MODS showed decreased level in ECMO (P -value = 0.03,
267 OR=2.82 [95% CI 0.63 – 12.45]) as compared to MODS (Fig. 2a). Interestingly, the two
268 lowest neutrophil counts were among MODS. Clinical data of these two patients
269 revealed that one patient did not survive and another had the PELOD score of 32, the
270 highest score among all patients, suggesting that these patients had a risk profile similar
271 to the ECMO patients despite not being started on ECMO.

272 We then examined the expression of marker genes of neutrophils (from
273 CIBERSORT), monocytes, cytokines and genes involved in NF- κ B and inflammatory
274 response from Hall et al., 2007 [16]. All the marker genes were down-regulated in
275 ECMO compared to MODS (Figure S2-S6). In addition to CIBERSORT, gene set
276 enrichment analysis of cell-type specific biomarker genes was performed in order to
277 confirm the findings. Neutrophil gene markers and genes involved in inflammatory
278 response displayed significantly decreased expression in ECMO compared to MODS
279 (P -value < 0.03) (Fig. 2b and 2c). Marker genes pertaining to monocytes, cytokines, and
280 NF- κ B displayed a significant enrichment in MODS compared to CT (P -value < 0.04)
281 (Fig. 2d-2f).

282 The finding of changes in the neutrophil count was independently validated using
283 additional single cell RNA-seq data of ECMO adult patients data [8], where we observed
284 decrease of expression of neutrophil gene markers and genes involved in inflammatory
285 response in deceased ECMO patients compared to patients that survived (Figure S7
286 and S8). Further paired comparison of neutrophil levels for each patient showed no

287 significant change across different time points (Fig. 2g and 2h).




288

289 **Fig. 2 Immune cell composition analyses in ECMO and MODS patients.** (a) Neutrophils
 290 counts computed from CIBERSORT decreased in ECMO ($P = 0.034$) compared to MODS at
 291 baseline. (b-f) Enrichment of genes involved in various immune responses (Monocytes,
 292 Cytokines, NF-kB, Neutrophils and Inflammation) in CT, MODS and ECMO at different time
 293 points (0h, 72h and 8d). Abundance of neutrophils in MODS (g) and ECMO (h) patients at

294 different time points (0h, 72h and 8days). Blue color - control (CT), grey color - MODS patients
295 and cyan color - ECMO patients.
296

297 Furthermore, differential expression (DE) analysis between MODS and control
298 (CT) as well as between ECMO and MODS was performed at baseline (0h). A total of
299 51 DE genes (\log_2 fold change ≥ 1 or ≤ -1 with false discovery rate (FDR) ≤ 0.2)
300 between MODS and CT, and 28 DE genes between ECMO and MODS were identified
301 at baseline (Fig. 3a). Comparison of DE genes from these two groups showed only one
302 pseudogene (RNU1-67P) common to these two DE lists. As expected, these DE genes
303 clearly separate CT, MODS and ECMO patients (Fig. 3b and 3c) in reduced
304 dimensional (PC) space. Heatmap visualization of these genes highlights their
305 differential patterns of expression between groups (Fig. 3d).

306 In addition, 50 and 32 DE genes between MODS and CT were identified at 72h
307 and 8d time points, respectively (Figure S9a), while 9 and 11 DE genes were identified
308 between ECMO and MODS at 72h and 8d time points, respectively (Figure S9b). Only
309 one gene (pseudogene- RNU1-67P) was common among all the three time points (0h,
310 72h and 8d) in both comparisons.



311

312 **Fig. 3 Differential gene expression analyses at baseline (0h).** (a) Comparison of differentially
 313 expressed (DE) genes between MODS vs. control (CT), and ECMO vs. MODS at baseline (0h).
 314 (b) First two principal components and (c) first three principal component analysis, using the
 315 union of DE genes obtained from the comparison between MODS and CT and that those
 316 between ECMO and MODS at baseline. Patients are clustered by their pathology group (CT,
 317 MODS and ECMO). (d) Expression of the DE genes.


318

319 **Biological processes and co-expression networks regulated by DE genes**

320 Gene ontology (GO) enrichment analysis of total DE genes from MODS to CT
 321 comparison revealed that immune-related (innate immune response, mast cell
 322 activation, neutrophil migration, interleukin-6 production, and cytokine production) and

323 fatty acid-related pathways are enriched in MODS compared to CT (corrected P -value \leq
324 0.01, Fig. 4a) (Table S3). Notable genes included in immune responses are *ADGRE2*,
325 *C3AR1*, *CD177*, *FCER1G*, *IRAK3*, *MMP8*, *PLSCR1*, *PPARG*, *SOCS3*, and *TLR5*.
326 Similar pathways were also observed in a previous analysis between MODS and CT [5].
327 In addition, gene expression related to epigenetic processes (e.g., regulation of gene
328 silence, DNA packaging, chromatin assembly) was activated in ECMO compared to
329 MODS (Fig. 4b and Table S4).

330 Further, co-expression analysis was performed to delineate the relationships
331 between gene expression and their regulated pathways. The TPM count of all the genes
332 for baseline patients was used to create co-expressed network modules. The DE genes
333 from MODS to CT and ECMO to MODS were mapped on these modules and identified
334 the corresponding modules. Two modules were identified in each comparison (Fig.4c
335 and 4d). Notably, some of the DE genes from MODS to CT were mapped on module
336 M15 of ECMO to MODS, deciphering the phase transition of MODS to ECMO support.
337 Module M14 was specific to the comparison of ECMO and MODS, whereas modules
338 M1 and M4 were specific to the comparison of MODS and CT. Pathways analysis of
339 each module showed that genes in module M1 were involved in immune responses
340 (Figure S10a) and genes in module M4 were involved in glucose metabolisms and
341 glycogen breakdown (Figure S10b). However, module M15 (shared by both
342 comparisons) showed enrichment of signaling pathways and proteins maintenance
343 (Figure S10c). Module M14 belonging to genes that differed between ECMO and MODS
344 was enriched with genes related to DNA damage, DNA maintenance and histone
345 acetylation (Figure S10d). Together, DE analysis showed enrichment of immune related



346

347 **Fig. 4 Gene enrichment and co-expression network analysis of DE genes in MODS and**

348 **CT, and in ECMO and MODS. (a) Gene ontology (GO) enrichment of DE genes from MODS to**

349 **CT showed their involvement in immune responses. (b) However, GO enrichment of DE genes**

350 **from ECMO to MODS displayed enrichment in epigenetic regulations. (c) The DE genes**

351 obtained from the comparison of MODS and CT were clustered into two separate groups. (d)
352 Similarly, two co-expression networks were created after mapping the DE genes in ECMO and
353 MODS. The highlighted genes in co-expressed networks are hub genes. Notably, many DE
354 genes from both comparisons were shared in module 15 (M15), suggested phase transition.
355 Size of circles in GO represents the number of mapped genes.

356

357 and glycogenolysis pathways in MODS, while protein maintenance and epigenetic-
358 related pathways were enriched in ECMO. The protein-protein interaction network of the
359 DE genes also revealed two distinct clusters: histone activation and blood coagulation
360 were uniquely enriched in ECMO (Figure S11).


361 The GO enrichment analysis and co-expression analysis of DE genes expressed
362 at 72h and 8d did not show any significantly enriched pathway in any of the
363 comparisons. This observation may suggest that the MODS and ECMO patients have
364 important physiological differences at baseline, but that other processes obfuscate
365 these differences as diverse disease processes and therapeutic interventions unfold.
366 Such baseline differences could be exploited for prognostic and potentially diagnostic
367 purposes.

368

369 **Identification of molecular signatures associated with ECMO**

370 In 2018, Sweeney et al. [4] evaluated four prognostic biomarker signatures consisting of
371 genes positively or negatively correlated with mortality in sepsis. We computed the
372 geometric mean of the expression of these signature genes and investigated whether
373 these values could be used as risk scores for MODS to ECMO progression. We
374 observed that the risk scores derived from the signature genes that are positively

375 correlated with mortality among sepsis patients could differentiate ECMO and MODS
 376 (P -value ranges from 0.04 to 0.01) (Figure S12).



377
 378 **Fig. 5 Univariate analyses of differentially expressed (DE) genes in ECMO and MODS.** (a)
 379 Odds ratio of the DE genes between ECMO and MODS (reference). A total of 6 genes from 28
 380 DE genes are significant (OR > 1 and P value < 0.05). (b) Expression of the DE genes in CT,
 381 ECMO and MODS patients at different time points. The higher expression of the genes in
 382 ECMO than in MODS at three time points (0h, 72h and 8d) suggests their strong association

383 with the deterioration from MODS to ECMO. Blue color displayed- control (CT), grey color
384 displayed- MODS patients and cyan color displayed- ECMO patients.*** P-value < 1E-06.
385

386 We next sought to derived the predictive power of the differentially expressed
387 genes identified between ECMO and MODS. Six genes from our differential gene
388 expression analysis demonstrated a very strong association with MODS for their
389 progression to ECMO (P -value < 0.04, Fig. 5a) and these were used to create a
390 signature for ECMO prediction. Most of these genes belong to the histone family
391 (*HIST2H3C*, *HIST1H4A*, *HIST1H2AI*, *HIST1H1B*, and *H1F0*, Table 2) and these were
392 expressed significantly higher in ECMO than MODS (P -value < 3.5e-6, Fig. 5b). In
393 addition, the Human Protein Atlas dataset showed the enhanced expression of these
394 genes in neutrophils (Figure S14).

395

396 **Table 2: List of signature genes strongly associated with ECMO.**


Gene	Ensemble	Log ₂ Fold change	Log CPM	P-value	Adj. P-value	Protein coding	Function
HIST2H3C	ENSG00000203811	2.11	3.88	9.10E-07	0.055	Y	histone cluster 2, H3c
HIST1H4A	ENSG00000278637	1.85	0.24	1.00E-06	0.061	Y	histone cluster 1, H4a
HIST1H2AI	ENSG00000196747	1.62	3.86	3.40E-06	0.207	Y	histone cluster 1, H2ai
HIST1H1B	ENSG00000184357	1.92	4.24	2.40E-06	0.147	Y	histone cluster 1, H1b
H1F0	ENSG00000189060	1.73	4.5	3.50E-06	0.212	Y	H1 histone family, member 0
DDIT4	ENSG00000168209	2.02	3.74	4.40E-07	0.026	Y	DNA-damage-inducible transcript 4

397

398 **Re-classification of patients and signature-based risk estimation**

399 Expression of the genes in our 6 gene risk signature was similar between CT and
400 MODS, but higher in ECMO than MODS (Fig. 6a). Interestingly, when the additional

401 time points (72h and 8d) were added, these signature genes were not different in
402 MODS and ECMO and could also be confirmed by the overlap of patients (Figure S15a
403 and S15b). The risk scores derived from these genes were significantly different
404 between ECMO and MODS (95%CI 1.54-42.91, P -value = $7E-04$, Fig. 6b) at baseline. In
405 contrast, risk scores of MODS patients at 72h and 8d are close to those of ECMO
406 patients at 72h and 8d (Fig. 6b).



407
408 **Fig. 6 Signature based re-classification of patients in the test (CT, MODS and ECMO)**
409 **dataset and validation dataset.** (a) Heatmaps showed the clustering of signature genes in
410 ECMO patients compared to control (CT) and MODS patients. Risk scores derived from the
411 signature genes showed difference in (b) ECMO and MODS in our data, and in (c) MODS and
412 noMODS (patients doesn't develop MODS) in the validation data (Cabrera et al., 2017). (d)
413 Receiver operating characteristics (ROC) of the classification using our data and the validation
414 data. A risk score for each patient was computed based on the geometric mean of the signature
415 gene expression. Risk scores were strongly associated with ECMO and can be helpful to predict
416 the probability of the MODS patients who require ECMO support.

417 Due to the lack of an appropriate pediatric cohort, we used previously published
418 microarray data of adult patients that developed MODS after a major trauma as validation
419 data. The authors had categorized the patients into two groups, those that developed
420 MODS and those that did not (noMODS), however these were more sick compared to
421 controls [9]. In their cohort, the risk score derived from our signature was significantly
422 higher (95%CI 1.02-10.35, P -value = $2E-02$) in MODS than noMODS (Fig. 6c). We further
423 found that our signature genes can also classify patients (noMODS, and MODS) in the
424 validation cohort at 0h (Figure S17a) as well as 72h timepoint (Figure S17b). Using logistic
425 regression to train the risk scores led to a remarkable separation (AUC of 0.91 [95%CI
426 0.79-1.00] for ECMO and MODS patients at baseline in our data and AUC of 0.8 [95%CI
427 0.53-0.93] in the validation set) of two group of patients from our data as well as validation
428 data, indicating a strong association of risk scores with MODS deterioration (Fig. 6d).

429

430 **Discussion**

431 The decision to initiate ECMO is often subjective, determined by the clinical judgement
432 of the multidisciplinary care team in a very stressful and dynamic setting as opposed to
433 quantitative measures of pathophysiology. Biological sampling of the exact organs
434 affected is impractical if not impossible, but circulating white blood cells may serve as a
435 proxy read out of stressed be experienced by multiple organ systems. We employed
436 transcriptomics of peripheral white cells in an effort to improve our understanding of the
437 response of circulating cells to multi-organ failure and its progression to either recovery
438 or cardiopulmonary collapse culminating in the need for extra corporeal life support.

439 White blood cells are uniquely suited for this because aside from a few
440 exceptions (e.g., memory T cells, some tissue macrophages), most of the mature blood
441 cell types are mitotically inactive, metabolically active and relatively short-lived with half-
442 lives ranging over hours to a few days. Thus, they are reflective of the environment they
443 course through [17]. We found the gene *AREG* which regulates Amphiregulin a
444 mediator for macrophage activity were preferentially activated in patients prior to ECMO
445 [18-19]. Amphiregulin has been shown to an essential cardioprotective mediator
446 produced by cardiac Ly6C macrophages in response to fluid overload, which is not
447 unusual in MODS [20].

448 The activation of immune response and glycogenolysis in MODS compared to
449 CT showed that patients in MODS need excessive energy for cellular homeostasis and
450 activation of immune response against the initial infections. However, during the
451 transition from MODS to ECMO, various signaling and protein maintenance pathways
452 also got activated. Notably, DNA repair, DNA methylation and other epigenetic changes
453 were activated in the patients who deceased further and needed ECMO support.

454 One of the key observations is the enrichment and strong association of histone
455 genes with ECMO. The histone octamer *HIST2H3C*, *HIST1H2AI*, *HIST1H4*, and
456 *HIST1H1B*, are genes that increase the availability of histones. Among these histones,
457 *HIST2H3C*, *HIST1H2AI*, and *HIST1H4A* are highly expressed in neutrophils (Figure
458 S14). Histones are a protein class, containing histone H1 and the core histones H2A,
459 H2B, H3, and H4 [21] that are involved in numerous biological processes, largely
460 through repressing transcription [22-23]. These are important due to their capability to
461 determine if DNA is accessible for transcription and they have a major impact on gene

462 expression, too [24]. However, to allow processes like transcription or replication, this
463 structure needs to change dynamically from a condensed state to an open one.

464 Genes that are associated with the histone cluster were found to be elevated.

465 Increases in serum histones have previously been shown to be elevated in patients with
466 sepsis and heart failure [25-26]. Higher concentrations of circulatory histones are
467 associated with poor survival in patients undergoing ECMO [27]. The increased
468 availability of histones in pathologies that concur with a prolonged inflammatory
469 response as is the case of sepsis. This is not only due to tissue damage but also to a
470 second source: activated neutrophils generate neutrophil extracellular traps (NETs),
471 structures made of cellular components which include specifically modified histones
472 [28]. Generation of circulating histones from NETs or from necrotic neutrophils implies
473 the release of a high concentration of histones to the bloodstream. Both processes,
474 NET and apoptosis of neutrophils and necrosis of neutrophils and other immune cells,
475 contribute to the pathogenesis of sepsis. NET however has been linked to organ failure
476 [29-31]. In this study we showed that these processes are active enough to be
477 uncovered by gene-expression.

478 This study shows that serial whole-blood transcriptomic profiling holds a great
479 promise to predict MODS patients, which may need EMCO support. Several published
480 gene signatures developed to predict mortality showed a significance in predicting
481 ECMO, but none of them suffice as a marker in our case. Our new signature genes
482 could remarkably differentiate MODS and ECMO. Their association with ECMO is
483 considerably strong and is also able to distinguish the severe and moderate MODS
484 patients in the validation cohort. The risk score derived from the signature genes for

485 each patient can be used to classify patients into two groups (ECMO and MODS) in our
486 cohort . This is important because in spite of the limited sample size, using pediatric
487 ECMO samples, the multiple time points and validation datasets increase the
488 robustness of our findings. Furthermore the study included patients, where sepsis was
489 not the primary cause of MODS indicating that histone signatures that occur in patients
490 with MODS do so regardless of the initial insult. The signature genes need further
491 evaluation by prospective studies in pediatric MODS/ECMO patients. Nevertheless, this
492 study is one of the first to demonstrate that the potential of exploring clinical and
493 transcriptomic features in identifying MODS patients from those requiring ECMO. In
494 addition, this work may be of some help to guide the treatment of those infected patients
495 at highest risk for progression to requiring ECMO support.

496

497 **Data and Code Availability**

498 The codes used in this analyses are available at [https://github.com/Bin-Chen-](https://github.com/Bin-Chen-Lab/MODS)
499 [Lab/MODS](#). The processed data used in this study is available through NCBI GEO
500 accession GSE144406.

501

502

503 **Acknowledgement**

504 Research reported in this publication was supported by the National Institute Of General
505 Medical Sciences of the National Institutes of Health under Award Number
506 R01GM134307. The content is solely the responsibility of the authors and does not
507 necessarily represent the official views of the National Institutes of Health. We would
508 like to thank Dr. Hui Shen for critical comments and the Van Andel Genomics Core for
509 providing sequencing facilities and services.

510

511 **Author contributions**

512 Conceived and designed the experiments: BC, SR and RS. Performed the experiments:
513 RS, ML and DM,. Analyzed the data: RS and PN. Contributed material/analysis tools:
514 KL, JX, EK, JWP, GZ, ASB. Wrote the paper: RS, BC, EK, SR and ML. Supervised the
515 study: BC and SR.

516 **References**

- 517 1. Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC,
518 Salloo A, et al. Global epidemiology of pediatric severe sepsis: the sepsis
519 prevalence, outcomes, and therapies study. *Am J Respir Crit Care Med.* 2015;
520 191(10): 1147-57. <https://doi.org/10.1164/rccm.201412-2323OC> PMID: 25734408.
- 521 2. Bestati N, Leteurtre S, Duhamel A, Proulx F, Grandbastien B, Lacroix J, et al.
522 Differences in organ dysfunctions between neonates and older children: a
523 prospective, observational, multicenter study. *Crit Care.* 2010; 14(6): R202.
524 <https://doi.org/10.1186/cc9323> PMID: 21062434.
- 525 3. Jenks CL, Raman L and Dalton HJ. Pediatric extracorporeal membrane
526 oxygenation. *Crit Care Clin.* 2017; 33(4):825-41. [https://doi.org/](https://doi.org/10.1016/j.ccc.2017.06.005)
527 10.1016/j.ccc.2017.06.005 PMID: 28887930.
- 528 4. Sweeney TE, Perumal TM, Henao R, Nichols M, Howrylak JA, Choi AM, et al. A
529 community approach to mortality prediction in sepsis via gene expression analysis.
530 *Nat Commun.* 2018; 9(1): 694. <https://doi.org/10.1038/s41467-018-03078-2> PMID:
531 29449546.
- 532 5. Sweeney TE, Azad TD, Donato M, Haynes WA, Perumal TM, Henao R et al.
533 Unsupervised analysis of transcriptomics in bacterial sepsis across multiple
534 datasets reveals three robust clusters. *Crit Care Med.* 2018; 46(6): 915-925.
535 <https://doi.org/10.1097/CCM.0000000000003084> PMID: 29537985.
- 536 6. Sweeney TE, Shidham A, Wong HR and Khatri P. A comprehensive time-course-
537 based multicohort analysis of sepsis and sterile inflammation reveals a robust
538 diagnostic gene set. *Sci Transl Med.* 2015; 7(287): 287ra71.
539 <https://doi.org/10.1126/scitranslmed.aaa5993> PMID: 25972003.
- 540 7. Cabrera CP, Manson J, Shepherd JM, Torrance HD, Watson D, Longhi MP, et al.
541 Signatures of inflammation and impending multiple organ dysfunction in the
542 hyperacute phase of trauma: A prospective cohort study. *PLoS Med.* 2017; 14(7):
543 e1002352. <https://doi.org/10.1371/journal> PMID.1002352.
- 544 8. Kort EJ, Weiland M, Grins E, Eugster E, Milliron HY, Kelty C, et al. Single cell
545 transcriptomics is a robust approach to defining disease biology in complex clinical
546 settings. *bioRxiv.* 2019; 568659. <https://doi.org/10.1101/568659>.

- 547 9. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR:
548 ultrafast universal RNA-seq aligner. *Bioinformatics*. 2013; 29(1): 15-21.
549 <https://doi.org/10.1093/bioinformatics/bts635> PMID:23104886.
- 550 10. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for
551 differential expression analysis of digital gene expression data. *Bioinformatics*.
552 2010; 26(1): 139-40. <https://doi.org/10.1093/bioinformatics/btp616>
553 PMID:19910308.
- 554 11. Russo PdST, Ferreira GR, Cardozo LE, Burger MC, Arias-Carrasco R, Maruyama
555 SR et al. "CEMiTool: a Bioconductor package for performing comprehensive
556 modular co-expression analyses." *BMC Bioinformatics*. 2018; 19(56): 1–13.
557 <https://doi.org/10.1186/s12859-018-2053-1> PMID: 29458351.
- 558 12. Yu G, Wang L, Han Y and He Q. clusterProfiler: an R package for comparing
559 biological themes among gene clusters. *OMICS*. 2012; 16(5): 284-287.
560 <https://doi.org/10.1089/omi.2011.0118> PMID:22455463.
- 561 13. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust
562 enumeration of cell subsets from tissue expression profiles. *Nat Methods*. 2015;
563 12(5): 453. <https://doi.org/10.1038/nmeth.3337> PMID: 25822800.
- 564 14. Schölkopf B, Smola AJ, Williamson RC, Bartlett PL. New support vector algorithms.
565 *Neural Comput*. 2000; 12: 1207–1245.
566 <https://doi.org/10.1162/089976600300015565>.
- 567 15. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an
568 open-source package for R and S+ to analyze and compare ROC curves. *BMC*
569 *bioinformatics*. 2011; 12(1): 77. <https://doi.org/10.1186/1471-2105-12-77>
570 [PMID:21414208](https://pubmed.ncbi.nlm.nih.gov/21414208/).
- 571 16. Hall MW, Gavrilin MA, Knatz NL, Duncan MD, Fernandez SA, Wewers MD.
572 Monocyte mRNA phenotype and adverse outcomes from pediatric multiple organ
573 dysfunction syndrome. *Pediatr Res*. 2007; 62(5):597.
574 <https://doi.org/10.1203/PDR.0b013e3181559774> PMID: 17805202.
- 575 17. Boettcher S, Manz MG. Regulation of inflammation-and infection-driven
576 hematopoiesis. *Trends Immunol*. 2017; 38(5): 345-57.
577 <https://doi.org/10.1016/j.it.2017.01.004> PMID: 28216309.

- 578 18. Meng C, Liu G, Mu H, Zhou M, Zhang S, Xu Y. Amphiregulin may be a new
579 biomarker of classically activated macrophages. *Biochem Biophys Res Commun.*
580 2015; 466(3): 393-9. <https://doi.org/10.1016/j.bbrc.2015.09.037> PMID: 26365345.
- 581 19. Zaiss DM, Gause WC, Osborne LC, Artis D. Emerging functions of amphiregulin
582 in orchestrating immunity, inflammation, and tissue repair. *Immunity.* 2015; 42(2):
583 216-26. <https://doi.org/10.1016/j.immuni.2015.01.020> PMID: 25692699.
- 584 20. Fujii K, Shibata M, Nakayama Y, Ogata F, Matsumoto S, Noshita K, et al. A heart–
585 brain–kidney network controls adaptation to cardiac stress through tissue
586 macrophage activation. *Nat Med.* 2017; 23(5): 611.
587 <https://doi.org/10.1038/nm.4326> PMID: 28394333.
- 588 21. Campos EI, Reinberg D. Histones: annotating chromatin. *Annu Rev Genet.* 2009;
589 43: 559–599. <https://doi.org/10.1146/annurev.genet.032608.103928> PMID:
590 19886812.
- 591 22. Grant PA. A tale of histone modifications. *Genome Biol.* 2001; 2(4): reviews0003-
592 1. <https://doi.org/10.1186/gb-2001-2-4-reviews0003> PMID: 11305943.
- 593 23. Jenuwein T, Allis CD. Translating the histone code. *Science.* 2001; 293(5532):
594 1074-80. <https://doi.org/10.1126/science.1063127> PMID: 11498575.
- 595 24. Falvo JV, Jasenosky LD, Kruidenier L, Goldfeld AE. Epigenetic control of cytokine
596 gene expression: regulation of the TNF/LT locus and T helper cell differentiation.
597 *Adv Immunol.* 2013; 118: 37-128. [https://doi.org/10.1016/B978-0-12-407708-
598 9.00002-9](https://doi.org/10.1016/B978-0-12-407708-9.00002-9) PMID: 23683942.
- 599 25. Ekaney ML, Otto GP, Sossdorf M, Sponholz C, Boehringer M, Loesche W, et al.
600 Impact of plasma histones in human sepsis and their contribution to cellular injury
601 and inflammation. *Crit Care.* 2014; 18(5): 543. [https://doi.org/10.1186/s13054-014-
602 0543-8](https://doi.org/10.1186/s13054-014-0543-8) PMID: 25260379.
- 603 26. Alhamdi Y, Abrams ST, Cheng Z, Jing S, Su D, Liu Z, et al. Circulating histones
604 are major mediators of cardiac injury in patients with sepsis. *Crit Care Med.* 2015;
605 43(10): 2094-103. <https://doi.org/10.1097/CCM.0000000000001162> PMID:
606 26121070.
- 607 27. Wen Z, Jin Y, Jiang X, Sun M, Arman N, Wen T, et al. Extracellular histones
608 indicate the prognosis in patients undergoing extracorporeal membrane

- 609 oxygenation therapy. *Perfusion*. 2019; 34(3): 211-216.
610 <https://doi.org/10.1177/0267659118809557> PMID: 30370815.
- 611 28. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, et al.
612 Extracellular histones are major mediators of death in sepsis. *Nat Med*. 2009;
613 15(11): 1318. <https://doi.org/10.1038/nm.2053> PMID: 19855397.
- 614 29. Czaikoski PG, Mota JM, Nascimento DC, Sônego F, Melo PH, Scortegagna GT,
615 et al. Neutrophil extracellular traps induce organ damage during experimental and
616 clinical sepsis. *PloS one*. 2016; 11(2): e0148142.
617 <https://doi.org/10.1371/journal.pone.0148142> PMID: 26849138.
- 618 30. Nakazawa D, Kumar SV, Marschner J, Desai J, Holderied A, Rath L, et al. Histones
619 and neutrophil extracellular traps enhance tubular necrosis and remote organ
620 injury in ischemic AKI. *J Am Soc Nephrol*. 2017; 28(6): 1753-68.
621 <https://doi.org/10.1681/ASN.2016080925> PMID: 28073931.
- 622 31. Li RH, Tablin F. A comparative review of neutrophil extracellular traps in sepsis.
623 *Front Vet Sci*. 2018; 5. <https://doi.org/10.3389/fvets.2018.00291> PMID: 30547040.

Supplementary information:

Gene expression signatures identify pediatric patients with multiple organ dysfunction who require advanced life support in the intensive care unit

Running title: Transcriptional signature for multiple organ dysfunction syndrome trajectory

Rama Shankar (ramashan@msu.edu)^{1,2}, Mara L. Leimanis (Mara.Leimanis@spectrumhealth.org)^{1,3}, Patrick A. Newbury (rnewbury@gmail.com)^{1,2}, Ke Liu (liuke2@msu.edu)^{1,2}, Jing Xing (xingjin1@msu.edu)^{1,2}, Derek Nedveck (dnedveck@gmail.com)⁴, Eric J. Kort (eric.kort@helendevoschildrens.org)^{1,5,6}, Jeremy W Prokop (prokopje@msu.edu)^{1,2}, Guoli Zhou (zhoug@msu.edu)⁷, André S Bachmann (bachma26@msu.edu)¹, Bin Chen (chenbi12@msu.edu)^{1,2*}, Surender Rajasekaran (surender.rajasekaran@spectrumhealth.org)^{1,3,4*}

1 Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, MI 49503, USA

2 Department of Pharmacology and Toxicology, College of Human Medicine, Michigan State University, Grand Rapids, MI 49503, USA

3 Pediatric Intensive Care Unit, Helen DeVos Children's Hospital, 100 Michigan Street NE, Grand Rapids, MI, 49503, USA

4 Office of Research, Spectrum Health, 15 Michigan Street NE, Grand Rapids, MI 49503, USA

5 DeVos Cardiovascular Program, Van Andel Research Institute and Fredrik Meijer Heart and Vascular Institute/Spectrum Health, Grand Rapids, MI 49503, USA

6 Pediatric Hospitalist Medicine, Helen DeVos Children's Hospital, 100 Michigan Street NE, Grand Rapids, MI, 49503, USA

7 Biomedical Research Informatics Core (BRIC), Clinical and Translational Sciences Institute (CTSI), Michigan State University, East Lansing, MI 48824, USA

* Correspondence: Dr. Bin Chen (chenbi12@msu.edu) and Dr. Surender Rajasekaran (surender.rajasekaran@spectrumhealth.org)




Figure S1. Correlation of neutrophils obtained from lab test data and derived from CIBERSORT. The values closely correlated with each other (Correlation value= 0.97).




Figure S2. Expression of monocyte genes (based on study of Hall et al., 2007) in control (CT), MODS and ECMO patients at different time points (0h, 72h and 8d). (* 0.01 < P value < 0.05; ** 0.001 < P value < 0.01; * 7.3e-6 < P value < 0.001).**




Figure S3. Expression of neutrophils genes (based on CIBERSORT cell marker) in control (CT), MODS and ECMO patients at different time points(0h, 72h and 8d). (* $0.05 > p \leq 0.01$ and ** $0.01 > p < 0.001$).




Figure S4. Expression of cytokines genes (based on study of Hall et al., 2007) in control (CT), MODS and ECMO patients at different time points(0h, 72h and 8d). (* $0.05 > p \leq 0.01$ and ** $0.01 > p < 2.5e-05$).




Figure S5. Expression of NF- κ B signaling pathway (based on study of Hall et al., 2007) in control (CT), MODS and ECMO patients at different time points(0h, 72h and 8d). (* $0.05 > p \leq 0.01$ and ** $0.01 > p < 7.3e-05$).




Figure S6. Expression of genes involved in inflammasome elements (based on study of Hall et al., 2007) in control (CT), MODS and ECMO patients at different time points(0h, 72h and 8d). (* $0.05 > p \leq 0.01$ and ** $0.01 > p < 7.8e-06$).




Figure S7. Expression of marker genes for neutrophils cells in single cell data of ECMO adult patients (Kort et al., 2019). Red- Surviving ECMO patients and Green- Died ECMO patients. (* $0.01 < P \text{ value} < 0.05$; ** $0.001 < P \text{ value} < 0.01$; * $2e-16 < P \text{ value} < 0.001$).**




Figure S8. Expression of genes involved in inflammatory response in each cell from the single cell data of ECMO adult patients (Kort et al., 2019). Red-Surviving ECMO patients and Green- Died ECMO patients. (* $0.01 < P \text{ value} < 0.05$ and ** $0.0008 < P \text{ value} < 0.01$).




Figure S9. Comparisons of differential gene expression. Venn diagram showing the comparisons of differentially expressed genes in between (a) MODS and control (CT) and (b) in between ECMO and MODS patients at different time points; baseline (0h), 72h and 8d.




Figure S10. Pathways enriched by the genes present in different co-expressed networks module. (a, b) Enriched pathways are shown by the DE genes from MODS vs CT and mapped on two co-expressed networks. (c) Enriched pathways shared by the DE genes in MODS vs CT and in ECMO vs MODS are shown. This showed the transition from MODS to ECMO. (d) In addition, epigenetic modifications related processes were activated in the severe MODS patients, who require ECMO support.




Figure S11. Interaction of genes associated with ECMO at baseline (0h). Two main networks (Histone interactions and gene markers for liver failure) were enriched.




Figure S12. Risk scores derived from the putative signatures predicted for sepsis patients (Sweeney et al., 2018). The signatures have been derived from different models namely, Duke, Sage LR, Sage RF and Stanford. These signatures are composed of two categories, i.e, positively and negatively associated with patients mortality. However, only the signature which are positively associated with patients mortality showed the difference in MODS and ECMO.




Figure S13. Odds ratio for clinical data. Clinical data available for all the ECMO and MODS patients at different time points were used to compute the odds ratio. Significantly (P value ≤ 0.03) higher odds ratio for Albumin was observed in ECMO as compared to MODS patients.




Figure S14. Expression pattern of some of histone genes in blood cells (Human protein atlas). It was observed that HIST2H3C, HIST1H4A, HIST1H2AI is highly expressed in neutrophils.




Figure S15. Labeled PCA comparing CT, MODS and ECMO at different time points. (a) Labeled PCA based on gene signature separated all the patients of different time points into CT, MODS and ECMO group. (b) PC1 and PC2 with PC3 provide more clear differentiation of patients.




Figure S16. Comparison of all genes in validation data (Cabrera et al., 2017). The violin plot displayed differences in the expression values in MODS and noMODS patients at ($P = 0.04$) 0h and ($P = 0.03$) 72h time point.




Figure S17. Labeled PCA separated the control (CT), noMODS (patients doesn't develop MODS) and MODS (develop MODS) patients in the validation cohort (Cabrera et al., 2017). (a) The labeled PCA using the signature genes associated with ECMO separated the MODS and noMODS. (b) The labeled PCA from different time points also separated MODS and noMODS patients with minimal overlap of patients at 72h. Although patients in the validation cohort data were adult, the remarkable separation indirectly validated the signature genes associated with pediatrics ECMO.

Table S1. Patient demographics at 72h and 8d time points.

RNA-Seq cohort						
Demographics	MODS	ECMO	P-value	MODS	ECMO	P-value
Time	72h			8d		
Number	16	5	-	9	4	-
Age (months)	-	-	-	-	-	-
Male	9	4	-	4	3	-
Female	7	1	-	5	1	-
BMI	-	-	-	-	-	-
Weight	-	-	-	-	-	-
Height	-	-	-	-	-	-
Mortality	-	-	-	-	-	-
Clinical Features						
Liver Failure (%)	-	-	-	-	-	-
Renal Failure	-	-	-	-	-	-
Creatinine	0.53(0.16-1.16)	0.95(0.25-2.5)	0.4	0.74(0.16-2.38)	0.63(0.15-1.86)	0.84
Bilirubin	1.25(0.1-11.5)	2.2(0.6-6.8)	0.51	0.61(0.2-2)	0.67(0.3-1.2)	0.83
AST	182.93(14-2010)	1798.2(45-4924)	0.19	34.87(11-112)	51.25(15-80)	0.39
Albumin	2.66(2-4.5)	3.58(2.6-4.4)	0.03*	2.85(2.2-3.6)	3.3(2.5-4.1)	0.28
Lactate	1.37(0.6-2.5)	1.8(1.2-3.2)	0.34	1.5(0.9-2.2)	1.47(1.3-1.8)	0.8
WBC	10.94(4.05-24.7)	9.97(5.72-14.9)	0.65	8.46(1.42-17.9)	11.59(9.7-13.38)	0.25
platelet	230(35-772)	111.8(73-148)	0.025*	141.25(97-161)	202.57(30-404)	0.23
CRP	83(0.9-189)	60.83(5.6-121)	0.49	78.12(8.6-167)	57.1(13-135)	0.69
Pelod Score	14.18(11-31)	17.2(1-32)	0.3	10.7 (1-21)	8.5(1-21)	0.33
Bacterial infection (%)	-	-	-	-	-	-
Viral infection (%)	-	-	-	-	-	-
Respiratory failure (%)	-	-	-	-	-	-
Neurological	-	-	-	-	-	-

Where relevant, mean(range). T-test and fisher's exact test was used to compute *P*-value between MODS and ECMO.

Table S2. List of differentially expressed genes in ECMO as compared to MODS patients at baseline (0h).

Gene	Ensemble	Log ² Fold Change	Log CPM	P-value	Adj. P-value	Protein coding	Function
RGS1	ENSG00000090104	4.12	2.75	1.3E-08	0.001	Y	regulator of G-protein signaling 1
APOH	ENSG00000091583	6.91	-2.00	2.5E-08	0.001	Y	apolipoprotein H (beta-2-glycoprotein I)
FAM83D	ENSG00000101447	1.97	-0.23	1.7E-07	0.010	Y	family with sequence similarity 83, member D
AREG	ENSG00000109321	3.51	0.49	2.0E-06	0.118	Y	amphiregulin
APOC1	ENSG00000130208	3.37	-1.93	2.0E-06	0.121	Y	apolipoprotein C-I
APCS	ENSG00000132703	5.12	-2.93	5.6E-07	0.034	Y	amyloid P component, serum
GC	ENSG00000145321	6.76	-2.08	3.0E-08	0.002	Y	group-specific component (vitamin D binding protein)
PRG3	ENSG00000156575	5.74	-1.27	5.9E-14	0.000	Y	proteoglycan 3
DUSP2	ENSG00000158050	3.13	1.79	3.4E-08	0.002	Y	dual specificity phosphatase 2
ALB	ENSG00000163631	7.92	1.80	3.6E-09	0.000	Y	albumin
KBTBD6	ENSG00000165572	1.69	3.50	1.2E-07	0.007	Y	kelch repeat and BTB (POZ) domain containing 6
WEE1	ENSG00000166483	1.54	2.52	1.5E-06	0.091	Y	WEE1 homolog (S. pombe)
DDIT4	ENSG00000168209	2.02	3.74	4.4E-07	0.026	Y	DNA-damage-inducible transcript 4
FGG	ENSG00000171557	6.02	-1.45	2.1E-07	0.013	Y	fibrinogen gamma chain
FGB	ENSG00000171564	7.08	-1.11	6.3E-08	0.004	Y	fibrinogen beta chain
SAA1	ENSG00000173432	7.55	-1.02	5.7E-08	0.003	Y	serum amyloid A1
HIST1H1B	ENSG00000184357	1.92	4.24	2.4E-06	0.147	Y	histone cluster 1, H1b
PRG2	ENSG00000186652	4.96	1.67	2.3E-08	0.001	Y	proteoglycan 2
H1F0	ENSG00000189060	1.73	4.50	3.5E-06	0.212	Y	H1 histone family, member 0
HIST1H2AI	ENSG00000196747	1.62	3.86	3.4E-06	0.207	Y	histone cluster 1, H2ai
RNA5S9	ENSG00000201321	5.54	-0.35	5.7E-08	0.003	Y	RNA, 5S ribosomal 9
HIST2H3C	ENSG00000203811	2.11	3.88	9.1E-07	0.055	Y	histone cluster 2, H3c
RNU1-67P	ENSG00000207175	3.94	0.78	1.2E-08	0.001	N	NA
HMGB1P30	ENSG00000244089	3.59	-2.84	5.2E-08	0.003	Y	high mobility group box 1 pseudogene 30
RP11-1H15.1	ENSG00000254765	3.83	-3.28	2.1E-06	0.125	N	NA
MRC1	ENSG00000260314	3.55	2.13	3.3E-08	0.002	Y	mannose receptor, C type 1
CTD-2033D15.2	ENSG00000276107	3.32	-0.61	1.1E-08	0.001	N	NA
HIST1H4A	ENSG00000278637	1.85	0.24	1.0E-06	0.061	Y	histone cluster 1, H4a

Table S3. Complete list of gene enriched in different processes in MODS as compared to CT at base line (0h).

GO ids	Description	p.adjust	qvalue	geneID
GO:0033003	regulation of mast cell activation	0.005	0.003	ADGRE2/FCER1G/PLSCR1
GO:0045088	regulation of innate immune response	0.005	0.003	IRAK3/PPARG/FCER1G/SOCS3/TLR5/PLSCR1
GO:0043300	regulation of leukocyte degranulation	0.005	0.003	ADGRE2/FCER1G/CD177
GO:0097530	granulocyte migration	0.005	0.003	ADGRE2/FCER1G/C3AR1/CD177
GO:0002886	regulation of myeloid leukocyte mediated immunity	0.006	0.004	ADGRE2/FCER1G/CD177
GO:0045576	mast cell activation	0.006	0.004	ADGRE2/FCER1G/PLSCR1
GO:0002526	acute inflammatory response	0.006	0.004	PPARG/FCER1G/C3AR1/PLSCR1
GO:0002431	Fc receptor mediated stimulatory signaling pathway	0.011	0.007	MYO10/FCER1G/PLSCR1
GO:0050727	regulation of inflammatory response	0.011	0.007	MM8/PPARG/FCER1G/C3AR1/SOCS3
GO:0097529	myeloid leukocyte migration	0.011	0.007	ADGRE2/FCER1G/C3AR1/CD177
GO:0032868	response to insulin	0.020	0.013	RETN/GRB10/PPARG/SOCS3
GO:0043302	positive regulation of leukocyte degranulation	0.020	0.013	FCER1G/CD177
GO:0002673	regulation of acute inflammatory response	0.021	0.013	PPARG/FCER1G/C3AR1
GO:0071404	cellular response to low-density lipoprotein particle stimulus	0.021	0.013	PPARG/FCER1G
GO:0072593	reactive oxygen species metabolic process	0.021	0.013	MM8/HK2/SH3PX2B/CD177
GO:1990266	neutrophil migration	0.021	0.013	FCER1G/C3AR1/CD177
GO:0060330	regulation of response to interferon-gamma	0.021	0.013	PPARG/SOCS3
GO:0060334	regulation of interferon-gamma-mediated signaling pathway	0.021	0.013	PPARG/SOCS3
GO:0071621	granulocyte chemotaxis	0.021	0.013	ADGRE2/FCER1G/C3AR1
GO:0043304	regulation of mast cell degranulation	0.021	0.013	ADGRE2/FCER1G
GO:0002888	positive regulation of myeloid leukocyte mediated immunity	0.021	0.013	FCER1G/CD177
GO:0033006	regulation of mast cell activation involved in immune response	0.021	0.013	ADGRE2/FCER1G
GO:0032675	regulation of interleukin-6 production	0.021	0.013	IRAK3/MM8/FCER1G
GO:0050594	response to lipoprotein particle	0.021	0.013	PPARG/FCER1G
GO:0061082	myeloid leukocyte cytokine production	0.021	0.013	IRAK3/FCER1G
GO:0071402	cellular response to lipoprotein particle stimulus	0.022	0.014	PPARG/FCER1G
GO:0032635	interleukin-6 production	0.022	0.014	IRAK3/MM8/FCER1G
GO:0046627	negative regulation of insulin receptor signaling pathway	0.022	0.014	GRB10/SOCS3
GO:1900077	negative regulation of cellular response to insulin stimulus	0.022	0.014	GRB10/SOCS3
GO:1903305	regulation of regulated secretory pathway	0.022	0.014	ADGRE2/FCER1G/CD177
GO:0032680	regulation of tumor necrosis factor production	0.024	0.015	IRAK3/MM8/FCER1G
GO:0032640	tumor necrosis factor production	0.024	0.015	IRAK3/MM8/FCER1G
GO:0002755	MyD88-dependent toll-like receptor signaling pathway	0.024	0.015	IRAK3/TLR5
GO:1903555	regulation of tumor necrosis factor superfamily cytokine production	0.024	0.015	IRAK3/MM8/FCER1G
GO:0071706	tumor necrosis factor superfamily cytokine production	0.025	0.016	IRAK3/MM8/FCER1G
GO:0045089	positive regulation of innate immune response	0.025	0.016	IRAK3/FCER1G/TLR5/PLSCR1
GO:0001959	regulation of cytokine-mediated signaling pathway	0.029	0.018	IRAK3/PPARG/SOCS3
GO:1903532	positive regulation of secretion by cell	0.029	0.018	RETN/MM8/FCER1G/CD177
GO:0043303	mast cell degranulation	0.029	0.018	ADGRE2/FCER1G
GO:0002279	mast cell activation involved in immune response	0.029	0.019	ADGRE2/FCER1G
GO:0002448	mast cell mediated immunity	0.030	0.019	ADGRE2/FCER1G
GO:0002429	immune response-activating cell surface receptor signaling pathway	0.030	0.019	MYO10/FCER1G/C3AR1/PLSCR1
GO:0060759	regulation of response to cytokine stimulus	0.030	0.019	IRAK3/PPARG/SOCS3
GO:0006911	phagocytosis, engulfment	0.030	0.019	PPARG/FCER1G
GO:0043434	response to peptide hormone	0.031	0.019	RETN/GRB10/PPARG/SOCS3
GO:1903307	positive regulation of regulated secretory pathway	0.031	0.019	FCER1G/CD177
GO:0051047	positive regulation of secretion	0.031	0.019	RETN/MM8/FCER1G/CD177
GO:2000377	regulation of reactive oxygen species metabolic process	0.031	0.020	MM8/HK2/CD177
GO:0009612	response to mechanical stimulus	0.031	0.020	RETN/PPARG/TLR5
GO:0017157	regulation of exocytosis	0.033	0.021	ADGRE2/FCER1G/CD177
GO:0032653	regulation of interleukin-10 production	0.034	0.021	MM8/FCER1G
GO:0050900	leukocyte migration	0.034	0.021	ADGRE2/FCER1G/C3AR1/CD177
GO:0032613	interleukin-10 production	0.034	0.021	MM8/FCER1G
GO:0046626	regulation of insulin receptor signaling pathway	0.034	0.021	GRB10/SOCS3
GO:0009024	plasma membrane invagination	0.034	0.021	PPARG/FCER1G
GO:0032869	cellular response to insulin stimulus	0.034	0.021	GRB10/PPARG/SOCS3
GO:0001960	negative regulation of cytokine-mediated signaling pathway	0.034	0.021	IRAK3/PPARG
GO:0045824	negative regulation of innate immune response	0.035	0.022	IRAK3/PPARG
GO:0043388	positive regulation of DNA binding	0.035	0.022	MM8/PPARG
GO:1900076	regulation of cellular response to insulin stimulus	0.035	0.022	GRB10/SOCS3
GO:0034394	protein localization to cell surface	0.035	0.022	FCER1G/CD177
GO:0046324	regulation of glucose import	0.035	0.022	GRB10/HK2
GO:0060761	negative regulation of response to cytokine stimulus	0.035	0.022	IRAK3/PPARG
GO:0045444	fat cell differentiation	0.037	0.023	RETN/PPARG/SH3PX2B
GO:0045600	positive regulation of fat cell differentiation	0.037	0.023	PPARG/SH3PX2B
GO:0031348	negative regulation of defense response	0.037	0.023	IRAK3/PPARG/SOCS3
GO:0010324	membrane invagination	0.038	0.024	PPARG/FCER1G
GO:0032418	lysosome localization	0.038	0.024	ADGRE2/FCER1G
GO:0030595	leukocyte chemotaxis	0.039	0.025	ADGRE2/FCER1G/C3AR1
GO:0046323	glucose import	0.042	0.026	GRB10/HK2
GO:0006909	phagocytosis	0.047	0.030	PPARG/MYO10/FCER1G
GO:0006801	superoxide metabolic process	0.048	0.031	SH3PX2B/CD177
GO:0038094	Fc-gamma receptor signaling pathway	0.048	0.031	MYO10/FCER1G
GO:0050766	positive regulation of phagocytosis	0.048	0.031	PPARG/FCER1G
GO:0010827	regulation of glucose transmembrane transport	0.049	0.031	GRB10/HK2
GO:0045921	positive regulation of exocytosis	0.051	0.032	FCER1G/CD177
GO:0034121	regulation of toll-like receptor signaling pathway	0.052	0.033	IRAK3/TLR5
GO:0032760	positive regulation of tumor necrosis factor production	0.053	0.033	MM8/FCER1G
GO:0002758	innate immune response-activating signal transduction	0.053	0.033	IRAK3/FCER1G/TLR5
GO:0051348	negative regulation of transferase activity	0.054	0.034	IRAK3/PPARG/SOCS3
GO:1903557	positive regulation of tumor necrosis factor superfamily cytokine production	0.054	0.034	MM8/FCER1G
GO:0002703	regulation of leukocyte mediated immunity	0.054	0.034	ADGRE2/FCER1G/CD177
GO:0002718	regulation of cytokine production involved in immune response	0.054	0.034	IRAK3/FCER1G
GO:0002699	positive regulation of immune effector process	0.054	0.034	ADGRE2/FCER1G/CD177
GO:0030100	regulation of endocytosis	0.054	0.034	PPARG/FCER1G/CD177
GO:0022617	extracellular matrix disassembly	0.054	0.034	MM8/SH3PX2B
GO:0032755	positive regulation of interleukin-6 production	0.055	0.036	MM8/FCER1G
GO:0002218	activation of innate immune response	0.057	0.036	IRAK3/FCER1G/TLR5
GO:1990823	response to leukemia inhibitory factor	0.059	0.037	HK2/SOCS3
GO:1990830	cellular response to leukemia inhibitory factor	0.059	0.037	HK2/SOCS3
GO:0071375	cellular response to peptide hormone stimulus	0.064	0.040	GRB10/PPARG/SOCS3
GO:0050764	regulation of phagocytosis	0.066	0.042	PPARG/FCER1G
GO:0060326	cell chemotaxis	0.067	0.042	ADGRE2/FCER1G/C3AR1
GO:0007229	integrin-mediated signaling pathway	0.069	0.043	FCER1G/CD177
GO:0071496	cellular response to external stimulus	0.069	0.043	PPARG/UPP1/TLR5
GO:0002367	cytokine production involved in immune response	0.069	0.044	IRAK3/FCER1G
GO:1904659	glucose transmembrane transport	0.069	0.044	GRB10/HK2
GO:0032103	positive regulation of response to external stimulus	0.069	0.044	MM8/FCER1G/C3AR1
GO:0030593	neutrophil chemotaxis	0.071	0.045	FCER1G/C3AR1
GO:0007596	blood coagulation	0.072	0.046	FCER1G/PLSCR1/CD177
GO:2000379	positive regulation of reactive oxygen species metabolic process	0.072	0.046	MM8/CD177
GO:0032963	collagen metabolic process	0.072	0.046	MM8/PPARG
GO:0002696	positive regulation of leukocyte activation	0.072	0.046	MM8/FCER1G/CD177
GO:0007599	hemostasis	0.072	0.046	FCER1G/PLSCR1/CD177
GO:0050817	coagulation	0.072	0.046	FCER1G/PLSCR1/CD177
GO:0008945	hexose transmembrane transport	0.072	0.046	GRB10/HK2
GO:0015749	monosaccharide transmembrane transport	0.074	0.047	GRB10/HK2
GO:0034219	carbohydrate transmembrane transport	0.075	0.048	GRB10/HK2
GO:0050867	positive regulation of cell activation	0.075	0.048	MM8/FCER1G/CD177
GO:0032368	regulation of lipid transport	0.079	0.050	RETN/PPARG
GO:1901653	cellular response to peptide	0.079	0.050	GRB10/PPARG/SOCS3
GO:0045765	regulation of angiogenesis	0.083	0.052	PPARG/HK2/C3AR1
GO:0038093	Fc receptor signaling pathway	0.083	0.052	MYO10/FCER1G

Table S4. Complete list of gene enriched in different processes in ECMO as compared to MODS at base line (0h).

GO Id	Description	p.adjust	qvalue	geneID
GO:0006342	chromatin silencing	0.00	0.00	HIST1H1B/H1F0/HIST2H3C/HIST2H3A/HIST1H4A
GO:0060968	regulation of gene silencing	0.00	0.00	HIST1H1B/H1F0/HIST2H3C/HIST2H3A/HIST1H4A
GO:0045814	negative regulation of gene expression, epigenetic	0.00	0.00	HIST1H1B/H1F0/HIST2H3C/HIST2H3A/HIST1H4A
GO:0006334	nucleosome assembly	0.00	0.00	HIST1H1B/H1F0/HIST2H3C/HIST2H3A/HIST1H4A
GO:0031497	chromatin assembly	0.00	0.00	HIST1H1B/H1F0/HIST2H3C/HIST2H3A/HIST1H4A
GO:0061045	negative regulation of wound healing	0.00	0.00	APOH/APCS/FGG/FGB
GO:0007596	blood coagulation	0.00	0.00	APOH/FGG/FGB/SAA1/HIST2H3C/HIST2H3A
GO:0031639	plasminogen activation	0.00	0.00	APOH/FGG/FGB
GO:0034728	nucleosome organization	0.00	0.00	HIST1H1B/H1F0/HIST2H3C/HIST2H3A/HIST1H4A
GO:0007599	hemostasis	0.00	0.00	APOH/FGG/FGB/SAA1/HIST2H3C/HIST2H3A
GO:0050817	coagulation	0.00	0.00	APOH/FGG/FGB/SAA1/HIST2H3C/HIST2H3A
GO:1903035	negative regulation of response to wounding	0.00	0.00	APOH/APCS/FGG/FGB
GO:0006333	chromatin assembly or disassembly	0.00	0.00	HIST1H1B/H1F0/HIST2H3C/HIST2H3A/HIST1H4A
GO:0072378	blood coagulation, fibrin clot formation	0.00	0.00	APOH/FGG/FGB
GO:0042730	fibrinolysis	0.00	0.00	APOH/FGG/FGB
GO:0006323	DNA packaging	0.00	0.00	HIST1H1B/H1F0/HIST2H3C/HIST2H3A/HIST1H4A
GO:0072376	protein activation cascade	0.00	0.00	APOH/APCS/FGG/FGB
GO:0000183	chromatin silencing at rDNA	0.00	0.00	HIST2H3C/HIST2H3A/HIST1H4A
GO:0065004	protein-DNA complex assembly	0.00	0.00	HIST1H1B/H1F0/HIST2H3C/HIST2H3A/HIST1H4A
GO:0002576	platelet degranulation	0.00	0.00	APOH/ALB/FGG/FGB
GO:0061041	regulation of wound healing	0.00	0.00	APOH/APCS/FGG/FGB
GO:0071103	DNA conformation change	0.00	0.00	HIST1H1B/H1F0/HIST2H3C/HIST2H3A/HIST1H4A
GO:0030195	negative regulation of blood coagulation	0.00	0.00	APOH/FGG/FGB
GO:1900047	negative regulation of hemostasis	0.00	0.00	APOH/FGG/FGB
GO:0071824	protein-DNA complex subunit organization	0.00	0.00	HIST1H1B/H1F0/HIST2H3C/HIST2H3A/HIST1H4A
GO:0031638	zymogen activation	0.00	0.00	APOH/FGG/FGB
GO:0050819	negative regulation of coagulation	0.00	0.00	APOH/FGG/FGB
GO:1903034	regulation of response to wounding	0.00	0.00	APOH/APCS/FGG/FGB
GO:0032102	negative regulation of response to external stimulus	0.00	0.00	APOH/APCS/FGG/FGB/SAA1
GO:0030193	regulation of blood coagulation	0.00	0.00	APOH/FGG/FGB
GO:0045652	regulation of megakaryocyte differentiation	0.00	0.00	HIST2H3C/HIST2H3A/HIST1H4A
GO:1900046	regulation of hemostasis	0.00	0.00	APOH/FGG/FGB
GO:0050818	regulation of coagulation	0.00	0.00	APOH/FGG/FGB
GO:0016584	nucleosome positioning	0.00	0.00	HIST1H1B/H1F0
GO:0060964	regulation of gene silencing by miRNA	0.00	0.00	HIST2H3C/HIST2H3A/HIST1H4A
GO:0060147	regulation of posttranscriptional gene silencing	0.00	0.00	HIST2H3C/HIST2H3A/HIST1H4A
GO:0060966	regulation of gene silencing by RNA	0.00	0.00	HIST2H3C/HIST2H3A/HIST1H4A
GO:0030219	megakaryocyte differentiation	0.00	0.00	HIST2H3C/HIST2H3A/HIST1H4A
GO:0031936	negative regulation of chromatin silencing	0.00	0.00	HIST1H1B/H1F0
GO:0051004	regulation of lipoprotein lipase activity	0.01	0.00	APOH/APOC1
GO:0045637	regulation of myeloid cell differentiation	0.01	0.00	APCS/HIST2H3C/HIST2H3A/HIST1H4A
GO:0034375	high-density lipoprotein particle remodeling	0.01	0.00	APOC1/ALB
GO:0006898	receptor-mediated endocytosis	0.01	0.01	APOC1/ALB/SAA1/MRC1
GO:0031935	regulation of chromatin silencing	0.01	0.01	HIST1H1B/H1F0
GO:0034116	positive regulation of heterotypic cell-cell adhesion	0.01	0.01	FGG/FGB
GO:0038111	interleukin-7-mediated signaling pathway	0.01	0.01	HIST2H3C/HIST2H3A
GO:0045907	positive regulation of vasoconstriction	0.01	0.01	FGG/FGB
GO:0098760	response to interleukin-7	0.01	0.01	HIST2H3C/HIST2H3A
GO:0098761	cellular response to interleukin-7	0.01	0.01	HIST2H3C/HIST2H3A